Our leadership team brings over 100 years of oncology drug development expertise, with contributions to more than 50 new drug applications.
Jeff is a dynamic BioPharma Executive and Scientific Leader who is adept at orchestrating the progression of therapeutic products from conceptualization to clinical development. His distinguished career is characterized by exceptional leadership, where he has led teams in pioneering programs across a spectrum of disease indications.
Marcio has over 25 years of experience in pharmaceutical drug discovery and biotech R&D. He has contributed to the discovery and development of 15 oncology clinical candidates and 12 IND submissions. He completed his Postdoc education at the NCI and has over forty publications and nine granted patents. He has experience vetting companies in his past role as Executive Director of Biotechnology Research at Eli Lilly.
Mayukh is an accomplished oncology clinical and translational development expert with extensive experience in driving innovations within the biotech and startup environment. With a proven track record in advancing over 20 investigational oncology assets from first-in-human to Phase III registration trials, Dr. Das possesses a deep understanding of the entire product lifecycle, from preclinical stages to commercial launches.
Kevin is an accomplished biomedical researcher, specialized in immune-based approaches to combat cancers and infectious diseases. His expertise ranges from understanding disease mechanisms, contributing to vaccine design and development, antibody discovery and engineering, and next-generation sequencing.
Brad is a seasoned Director of Operations with over a decade of experience where he has masterfully integrated technology with biology. At Irazu, he spearheaded the transformation from a small analytical lab to a comprehensive microbial manufacturing suite, analytical lab, and cell culture lab. With an unwavering commitment to scaling up operations while maintaining stringent control measures, Brad is driven by his passion for delivering safe and effective medicines to patients in need.
Dr. Azad is Co-Director of Cancer Genetics and Epigenetics at Johns Hopkins Hospital and directs the Developmental Therapeutics Clinical Trials Program for the Sidney Kimmel Cancer Center. Her research focuses on early-phase drug development and her clinical expertise is in cancers of the GI tract, with a concentration in CRC.
Dr. Rapoport is the Gary Jobson Professor of Clinical Oncology at the University of Maryland School of Medicine. An MIT and Harvard graduate, Dr. Rapoport has over 30 years of experience specializing in advanced and effective methods for cancer treatment, including autologous and allogeneic stem cell transplants and cellular immunotherapy.
Dr. Macaya is the former ambassador of Costa Rica to the United States and is currently the Menschel Senior Leadership Fellow at Harvard T.H. Chan School of Public Health. In his former role as Executive President and Chairman of the Costa Rican Social Security, he was responsible for the provision of all public health care in Costa Rica and led the nation’s response to the COVID-19 pandemic.
Paul is Sr. Director of National Services and Support at Illumina. He has twenty years of experience in advancing next generation sequencing for discovery of antigens or neoantigens and markers for cancer.
A Hopkins-trained internist and pathologist, Dr. Popper is Co-founder and President of Popper and Co., a consulting firm that addresses inefficiencies in health care by helping life science companies develop and commercialize new technology. Additionally, Dr. Popper is Chair of the Innovation and Commercialization Committee at JHU School of Public Health and an advisor of multiple clinical and healthcare companies.
Marco is a successful entrepreneur and former CEO and Chairman of Paragon Biosciences, Inc., a CDMO specialized in product development and GMP manufacturing of vaccines and viral vectors for gene therapy. Paragon was acquired by Catalent Pharma in 2019 for $1.2 B.
Mr. Berens is Chairman and President of Wexford Science and Technology. His experience includes the development of 18 innovation communities in partnership with leading research universities around the country offering state-of-the-art research and laboratory spaces.
Mr. Kohr is a founding member and Chief Executive Officer of Evergreen Advisors, LLC. He has over 30 years of experience in advising early-stage growth and middle-market companies on finance, recapitalization and exit strategies.
